Open Access. Powered by Scholars. Published by Universities.®
- Institution
- Keyword
-
- ALZHEIMERS-DISEASE (1)
- Acquired resistance (1)
- Amino acid transporter (1)
- Amyotrophic Lateral Sclerosis with Cognitive Impairment (ALSci) (1)
- BARNES MAZE (1)
-
- Behavioral Sciences (1)
- CIRCADIAN PHASE (1)
- Chronic Traumatic Encephalopathy (CTE) (1)
- Cognitive impairment (1)
- Cyclin-dependent kinase (1)
- Dermatology (1)
- Enzymes (1)
- Ethovision (1)
- Hippocampus (1)
- INBRED MOUSE STRAINS (1)
- Life Sciences & Biomedicine (1)
- MEMORY DEFICITS (1)
- MORRIS WATER-MAZE (1)
- Mammals (1)
- Mental retardation (1)
- Molecular mechanism (1)
- Morris water maze (1)
- Muscimol (1)
- Neurodegeneration (1)
- Neurosciences (1)
- Neurosciences & Neurology (1)
- Oncology (1)
- PERFORMANCE (1)
- SEARCH STRATEGIES (1)
- SYNAPTIC PLASTICITY (1)
- Publication
- Publication Type
Articles 1 - 3 of 3
Full-Text Articles in Entire DC Network
Slc36a1-Mtorc1 Signaling Drives Acquired Resistance To Cdk4/6 Inhibitors., Akihiro Yoshida, Yiwen Bu, Shuo Qie, John Wrangle, E. Ramsay Camp, E. Starr Hazard, Gary Hardiman, Renée De Leeuw, Karen E. Knudsen, J. Alan Diehl
Slc36a1-Mtorc1 Signaling Drives Acquired Resistance To Cdk4/6 Inhibitors., Akihiro Yoshida, Yiwen Bu, Shuo Qie, John Wrangle, E. Ramsay Camp, E. Starr Hazard, Gary Hardiman, Renée De Leeuw, Karen E. Knudsen, J. Alan Diehl
Department of Cancer Biology Faculty Papers
The cyclin-dependent kinase 4/6 (CDK4/6) kinase is dysregulated in melanoma, highlighting it as a potential therapeutic target. CDK4/6 inhibitors are being evaluated in trials for melanoma and additional cancers. While beneficial, resistance to therapy is a concern, and the molecular mechanisms of such resistance remain undefined. We demonstrate that reactivation of mammalian target of rapamycin 1 (mTORC1) signaling through increased expression of the amino acid transporter, solute carrier family 36 member 1 (SLC36A1), drives resistance to CDK4/6 inhibitors. Increased expression of SLC36A1 reflects two distinct mechanisms: (i) Rb loss, which drives SLC36A1 via reduced suppression of E2f; (ii) fragile X …
The Role Of The Tau N-Terminal Phosphatase-Activating Domain And Phosphorylation At Thr175 In The Formation Of Tau Cytoplasmic Inclusions, Matthew A. Hintermayer
The Role Of The Tau N-Terminal Phosphatase-Activating Domain And Phosphorylation At Thr175 In The Formation Of Tau Cytoplasmic Inclusions, Matthew A. Hintermayer
Electronic Thesis and Dissertation Repository
Cytoplasmic inclusions and fibrils of the microtubule-associated protein tau (tau protein) are a key neuropathological hallmark in tauopathies, including Alzheimer’s disease, chronic traumatic encephalopathy, and amyotrophic lateral sclerosis with cognitive impairment. Previous research has demonstrated that the phosphorylation of tau protein at Thr175 is sufficient for the initiation of fibril formation both in vitro and in vivo. Here we use mutated tau protein constructs to demonstrate that phosphorylation at Thr175 results in the aberrant exposure of an N-terminal phosphatase-activating domain (PAD). The tau PAD interacts with protein phosphatase 1 (PP1) leading to the activation of glycogen synthase …
Large-Scale Validation Of The Paddling Pool Task In The Clockmaze For Studying Hippocampus-Based Spatial Cognition In Mice, R. Sankowski, T. S. Huerta, R. Kalra, T. J. Klein, J. Strohl, A. Al-Abed, S. Robbiati, P. T. Huerta
Large-Scale Validation Of The Paddling Pool Task In The Clockmaze For Studying Hippocampus-Based Spatial Cognition In Mice, R. Sankowski, T. S. Huerta, R. Kalra, T. J. Klein, J. Strohl, A. Al-Abed, S. Robbiati, P. T. Huerta
Journal Articles
No abstract provided.